Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in giant cell arteritis
NL-OMON59064Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in giant cell arteritis (GCA) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Sustained remission at Week 52. Started Aug 2019; status: completed.
02
Drugs
upadacitinib
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NL-OMON59064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59064.